CY1123350T1 - Θεραπευτικα σχηματα καi μεθοδοι αντιμετωπισης σκληρυνσης κατα πλακας μεσω χρησης οφατουμουμαμπης - Google Patents

Θεραπευτικα σχηματα καi μεθοδοι αντιμετωπισης σκληρυνσης κατα πλακας μεσω χρησης οφατουμουμαμπης

Info

Publication number
CY1123350T1
CY1123350T1 CY20201100861T CY201100861T CY1123350T1 CY 1123350 T1 CY1123350 T1 CY 1123350T1 CY 20201100861 T CY20201100861 T CY 20201100861T CY 201100861 T CY201100861 T CY 201100861T CY 1123350 T1 CY1123350 T1 CY 1123350T1
Authority
CY
Cyprus
Prior art keywords
treatment
methods
shelder
ofatumumambi
plaque
Prior art date
Application number
CY20201100861T
Other languages
English (en)
Inventor
Erik WALLSTRÖM
Marina SAVELIEVA PRAZ
Algirdas Jonas KAKARIEKA WEISSKOPF
Joseph Michael KAHN
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1123350T1 publication Critical patent/CY1123350T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η αποκάλυψη απευθύνεται σε θεραπευτικά σχήματα για τη θεραπεία της Σκλήρυνσης κατά πλάκας (Multiple Sclerosis, MS). Αυτές οι μέθοδοι χρησιμοποιούν τη χορήγηση οφατουμουμάμπης, ενός αντι-CD20 μονοκλωνικού αντισώματος, στον ασθενή κατά τη διάρκεια ενός δοσολογικού σχήματος φόρτωσης και ενός σχήματος συντήρησης.
CY20201100861T 2016-08-15 2020-09-11 Θεραπευτικα σχηματα καi μεθοδοι αντιμετωπισης σκληρυνσης κατα πλακας μεσω χρησης οφατουμουμαμπης CY1123350T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662374986P 2016-08-15 2016-08-15
PCT/IB2017/054909 WO2018033841A1 (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Publications (1)

Publication Number Publication Date
CY1123350T1 true CY1123350T1 (el) 2021-12-31

Family

ID=59901554

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100861T CY1123350T1 (el) 2016-08-15 2020-09-11 Θεραπευτικα σχηματα καi μεθοδοι αντιμετωπισης σκληρυνσης κατα πλακας μεσω χρησης οφατουμουμαμπης

Country Status (24)

Country Link
US (3) US11161909B2 (el)
EP (4) EP3497132B1 (el)
JP (2) JP6851391B2 (el)
KR (2) KR20190038914A (el)
CN (1) CN109641965A (el)
AU (2) AU2017311664B2 (el)
CA (2) CA3030530C (el)
CY (1) CY1123350T1 (el)
DE (1) DE202017007542U1 (el)
DK (2) DK3497132T3 (el)
ES (2) ES2821924T3 (el)
FI (1) FI3733712T3 (el)
HR (2) HRP20230894T1 (el)
HU (2) HUE051948T2 (el)
IL (3) IL302488A (el)
LT (2) LT3733712T (el)
MX (1) MX2019001860A (el)
PL (2) PL3733712T3 (el)
PT (2) PT3733712T (el)
RS (2) RS64541B1 (el)
RU (1) RU2749951C2 (el)
SI (2) SI3733712T1 (el)
TW (1) TWI752995B (el)
WO (1) WO2018033841A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3733712T3 (pl) * 2016-08-15 2023-10-16 Novartis Ag Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu
EP3864053B1 (en) 2019-09-11 2023-07-05 Novartis AG Treatment of rms by switching therapy
MX2022003030A (es) 2019-09-11 2022-04-07 Novartis Ag Tratamiento de afecciones distintas de la esclerosis multiple en pacientes tratados con ofatumumab.
CN117529336A (zh) * 2021-04-14 2024-02-06 诺华股份有限公司 用于治疗亚洲患者的多发性硬化症的奥法木单抗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
JP2014506258A (ja) * 2011-01-10 2014-03-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 新規使用
MX363819B (es) * 2012-02-08 2019-04-03 Igm Biosciences Inc Uniones a cdim y sus usos.
GEP201706748B (en) 2012-08-10 2017-10-10 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
WO2016123329A2 (en) * 2015-01-28 2016-08-04 Genentech, Inc. Gene expression markers and treatment of multiple sclerosis
PL3733712T3 (pl) * 2016-08-15 2023-10-16 Novartis Ag Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu

Also Published As

Publication number Publication date
WO2018033841A1 (en) 2018-02-22
LT3733712T (lt) 2023-09-11
EP3733712A1 (en) 2020-11-04
TW201808333A (zh) 2018-03-16
PL3733712T3 (pl) 2023-10-16
SI3733712T1 (sl) 2023-12-29
CA3030530A1 (en) 2018-02-22
HRP20201388T1 (hr) 2020-11-27
DK3497132T3 (da) 2020-09-07
IL276890A (en) 2020-10-29
RU2021105514A3 (el) 2022-02-08
PL3497132T3 (pl) 2020-11-30
PT3497132T (pt) 2020-09-25
EP3733712B1 (en) 2023-05-24
ES2954259T3 (es) 2023-11-21
RU2019107146A3 (el) 2020-09-15
HRP20230894T1 (hr) 2023-11-24
HUE063625T2 (hu) 2024-01-28
JP7198786B2 (ja) 2023-01-04
AU2020201112A1 (en) 2020-03-05
AU2020201112B2 (en) 2021-07-22
US20240150485A1 (en) 2024-05-09
SI3497132T1 (sl) 2020-10-30
PT3733712T (pt) 2023-08-31
US20220081488A1 (en) 2022-03-17
EP4252847A2 (en) 2023-10-04
TWI752995B (zh) 2022-01-21
CN109641965A (zh) 2019-04-16
JP6851391B2 (ja) 2021-03-31
RS60807B1 (sr) 2020-10-30
DE202017007542U1 (de) 2022-07-19
JP2020100630A (ja) 2020-07-02
EP3497132B1 (en) 2020-06-24
RU2749951C2 (ru) 2021-06-21
US11161909B2 (en) 2021-11-02
IL302488A (en) 2023-06-01
RU2021105514A (ru) 2021-04-19
EP3497132A1 (en) 2019-06-19
AU2017311664B2 (en) 2020-01-02
LT3497132T (lt) 2020-10-12
US20190177424A1 (en) 2019-06-13
HUE051948T2 (hu) 2021-03-29
IL276890B2 (en) 2023-10-01
EP4371611A2 (en) 2024-05-22
AU2017311664A1 (en) 2019-01-31
DK3733712T3 (da) 2023-08-21
RS64541B1 (sr) 2023-09-29
KR20190038914A (ko) 2019-04-09
EP4252847A3 (en) 2023-11-15
ES2821924T3 (es) 2021-04-28
MX2019001860A (es) 2019-07-08
KR20200136503A (ko) 2020-12-07
IL264804B (en) 2020-09-30
CA3101514A1 (en) 2018-02-22
CA3030530C (en) 2021-02-23
JP2019511506A (ja) 2019-04-25
IL276890B1 (en) 2023-06-01
FI3733712T3 (fi) 2023-08-22
RU2019107146A (ru) 2020-09-15

Similar Documents

Publication Publication Date Title
CY1123350T1 (el) Θεραπευτικα σχηματα καi μεθοδοι αντιμετωπισης σκληρυνσης κατα πλακας μεσω χρησης οφατουμουμαμπης
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
CY1123688T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20
MX2020004948A (es) Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
CY1123256T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
EA201692436A1 (ru) Медицинское применение
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
MX2022015115A (es) Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.
CO2020004831A2 (es) Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa
EA201790164A1 (ru) Комбинированная терапия рака
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
EA201792209A1 (ru) Схема введения пропущенных доз инъекционных сложных эфиров палиперидона длительного действия
CY1122508T1 (el) Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MX2018002554A (es) Combinaciones de inhibidores de btk para tratar mieloma multiple.
CY1123982T1 (el) Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ)
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
CL2019000846A1 (es) Proteína terapéutica.
CY1120176T1 (el) Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης
EA201792314A1 (ru) Фармацевтическая комбинация эверолимуса и дактолисиба
MX2021004120A (es) Regimen de dosificacion para antagonistas de tfpi.